Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 851, doi. 10.1007/s40262-015-0239-5
- By:
- Publication type:
- Article
Works matching IS 03125963 AND DT 2015 AND VI 54 AND IP 8
Results: 7
1
2
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 859, doi. 10.1007/s40262-015-0240-z
- By:
- Publication type:
- Article
3
Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 875, doi. 10.1007/s40262-015-0245-7
- By:
- Publication type:
- Article
4
The Pharmacogenetics of Tramadol.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 825, doi. 10.1007/s40262-015-0268-0
- By:
- Publication type:
- Article
5
A Comprehensive Review of Drug-Drug Interactions with Metformin.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 811, doi. 10.1007/s40262-015-0270-6
- By:
- Publication type:
- Article
6
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 797, doi. 10.1007/s40262-015-0273-3
- By:
- Publication type:
- Article
7
Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 8, p. 837, doi. 10.1007/s40262-015-0238-6
- By:
- Publication type:
- Article